Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.50
MDCO's Cash to Debt is ranked higher than
71% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. MDCO: 1.50 )
MDCO' s 10-Year Cash to Debt Range
Min: 1.24   Max: No Debt
Current: 1.5

Equity to Asset 0.49
MDCO's Equity to Asset is ranked higher than
61% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. MDCO: 0.49 )
MDCO' s 10-Year Equity to Asset Range
Min: 0.49   Max: 0.85
Current: 0.49

0.49
0.85
F-Score: 4
Z-Score: 1.62
M-Score: -2.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -8.91
MDCO's Operating margin (%) is ranked higher than
57% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. MDCO: -8.91 )
MDCO' s 10-Year Operating margin (%) Range
Min: -401.44   Max: 14.87
Current: -8.91

-401.44
14.87
Net-margin (%) -4.45
MDCO's Net-margin (%) is ranked higher than
58% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. MDCO: -4.45 )
MDCO' s 10-Year Net-margin (%) Range
Min: -385.2   Max: 29.79
Current: -4.45

-385.2
29.79
ROE (%) -3.55
MDCO's ROE (%) is ranked higher than
60% of the 895 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. MDCO: -3.55 )
MDCO' s 10-Year ROE (%) Range
Min: -237.8   Max: 35
Current: -3.55

-237.8
35
ROA (%) -1.78
MDCO's ROA (%) is ranked higher than
61% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. MDCO: -1.78 )
MDCO' s 10-Year ROA (%) Range
Min: -183.56   Max: 24.65
Current: -1.78

-183.56
24.65
ROC (Joel Greenblatt) (%) -73.03
MDCO's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. MDCO: -73.03 )
MDCO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -16443.26   Max: 300.56
Current: -73.03

-16443.26
300.56
Revenue Growth (3Y)(%) 8.10
MDCO's Revenue Growth (3Y)(%) is ranked higher than
81% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. MDCO: 8.10 )
MDCO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 88.9
Current: 8.1

0
88.9
EBITDA Growth (3Y)(%) -52.10
MDCO's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MDCO: -52.10 )
MDCO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -7.9
Current: -52.1

» MDCO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

MDCO Guru Trades in Q1 2014

RS Investment Management 523,764 sh (New)
Jim Simons 53,042 sh (New)
Chuck Royce 6,115,200 sh (+32.94%)
Vanguard Health Care Fund 4,700,058 sh (+2.2%)
George Soros Sold Out
Joel Greenblatt Sold Out
John Hussman 67,000 sh (-35.58%)
» More
Q2 2014

MDCO Guru Trades in Q2 2014

Joel Greenblatt 194,954 sh (New)
George Soros 75,000 sh (New)
Chuck Royce 6,656,025 sh (+8.84%)
Vanguard Health Care Fund 4,700,058 sh (unchged)
John Hussman Sold Out
Jim Simons Sold Out
RS Investment Management 484,842 sh (-7.43%)
» More
Q3 2014

MDCO Guru Trades in Q3 2014

Vanguard Health Care Fund 4,762,730 sh (+1.33%)
Chuck Royce 6,729,175 sh (+1.1%)
George Soros Sold Out
RS Investment Management 477,466 sh (-1.52%)
Joel Greenblatt 24,009 sh (-87.68%)
» More
Q4 2014

MDCO Guru Trades in Q4 2014

Steven Cohen 221,600 sh (New)
Vanguard Health Care Fund 5,461,430 sh (+14.67%)
Joel Greenblatt Sold Out
RS Investment Management 476,998 sh (-0.1%)
Chuck Royce 4,647,740 sh (-30.93%)
» More
» Details

Insider Trades

Latest Guru Trades with MDCO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-12-31 Sold Out 0.01%$20.36 - $27.96 $ 29.7720%0
Joel Greenblatt 2014-09-30 Reduce -87.68%0.06%$22.95 - $29.64 $ 29.7717%24009
George Soros 2014-09-30 Sold Out 0.02%$22.95 - $29.64 $ 29.7717%0
John Hussman 2014-06-30 Sold Out 0.14%$24.02 - $29.57 $ 29.7712%0
Joel Greenblatt 2014-06-30 New Buy0.07%$24.02 - $29.57 $ 29.7712%194954
George Soros 2014-06-30 New Buy0.02%$24.02 - $29.57 $ 29.7712%75000
John Hussman 2014-03-31 Reduce -35.58%0.1%$27.9 - $40.39 $ 29.77-11%67000
George Soros 2014-03-31 Sold Out 0.02%$27.9 - $40.39 $ 29.77-11%0
Joel Greenblatt 2014-03-31 Sold Out 0.01%$27.9 - $40.39 $ 29.77-11%0
George Soros 2013-12-31 Reduce -80%0.07%$31.48 - $38.91 $ 29.77-17%50000
Joel Greenblatt 2013-12-31 New Buy0.01%$31.48 - $38.91 $ 29.77-17%13990
John Hussman 2013-09-30 Reduce -79.73%0.57%$29.68 - $34.54 $ 29.77-6%104000
Vanguard Health Care Fund 2013-09-30 Add 219.22%0.33%$29.68 - $34.54 $ 29.77-6%4250415
George Soros 2013-09-30 Add 66.67%0.04%$29.68 - $34.54 $ 29.77-6%250000
John Hussman 2013-06-30 Reduce -26.29%0.22%$30.76 - $37.1 $ 29.77-11%513000
Vanguard Health Care Fund 2013-06-30 Add 181.56%0.1%$30.76 - $37.1 $ 29.77-11%1331500
George Soros 2013-06-30 Add 57.89%0.02%$30.76 - $37.1 $ 29.77-11%150000
John Burbank 2013-03-31 Sold Out 0.09%$23.97 - $33.41 $ 29.77-2%0
Vanguard Health Care Fund 2013-03-31 New Buy0.06%$23.97 - $33.41 $ 29.77-2%472900
George Soros 2013-03-31 New Buy0.04%$23.97 - $33.41 $ 29.77-2%95000
John Burbank 2012-12-31 New Buy0.09%$20.34 - $26.64 $ 29.7731%100000
John Hussman 2012-09-30 New Buy0.38%$22.88 - $26.68 $ 29.7719%615000
Joel Greenblatt 2012-09-30 Sold Out 0.03%$22.88 - $26.68 $ 29.7719%0
Joel Greenblatt 2012-06-30 Reduce -79.52%0.11%$19.56 - $22.98 $ 29.7740%16302
George Soros 2012-06-30 Sold Out 0.07%$19.56 - $22.98 $ 29.7740%0
George Soros 2012-03-31 Reduce -80%0.8%$18.22 - $22.28 $ 29.7756%250000
George Soros 2011-12-31 Reduce -26.47%0.11%$16.6 - $20 $ 29.7760%1250000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 40.49
MDCO's Forward P/E is ranked higher than
79% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 58.14 vs. MDCO: 40.49 )
N/A
P/B 2.10
MDCO's P/B is ranked higher than
84% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. MDCO: 2.10 )
MDCO' s 10-Year P/B Range
Min: 1.14   Max: 11.31
Current: 2.1

1.14
11.31
P/S 2.60
MDCO's P/S is ranked higher than
81% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. MDCO: 2.60 )
MDCO' s 10-Year P/S Range
Min: 0.9   Max: 16.72
Current: 2.6

0.9
16.72
PFCF 42.40
MDCO's PFCF is ranked higher than
89% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MDCO: 42.40 )
MDCO' s 10-Year PFCF Range
Min: 6.54   Max: 305.88
Current: 42.4

6.54
305.88
POCF 28.63
MDCO's POCF is ranked higher than
84% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.53 vs. MDCO: 28.63 )
MDCO' s 10-Year POCF Range
Min: 8.63   Max: 296.67
Current: 28.63

8.63
296.67
EV-to-EBIT -28.32
MDCO's EV-to-EBIT is ranked higher than
62% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.09 vs. MDCO: -28.32 )
MDCO' s 10-Year EV-to-EBIT Range
Min: -824.5   Max: 790.2
Current: -28.32

-824.5
790.2
Shiller P/E 48.70
MDCO's Shiller P/E is ranked higher than
82% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 103.75 vs. MDCO: 48.70 )
MDCO' s 10-Year Shiller P/E Range
Min: 25.91   Max: 748.5
Current: 48.7

25.91
748.5
Current Ratio 1.63
MDCO's Current Ratio is ranked higher than
82% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.36 vs. MDCO: 1.63 )
MDCO' s 10-Year Current Ratio Range
Min: 0.64   Max: 6.54
Current: 1.63

0.64
6.54
Quick Ratio 1.43
MDCO's Quick Ratio is ranked higher than
83% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. MDCO: 1.43 )
MDCO' s 10-Year Quick Ratio Range
Min: 0.64   Max: 6.08
Current: 1.43

0.64
6.08
Days Inventory 105.59
MDCO's Days Inventory is ranked higher than
85% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.90 vs. MDCO: 105.59 )
MDCO' s 10-Year Days Inventory Range
Min: 15.56   Max: 1606.52
Current: 105.59

15.56
1606.52
Days Sales Outstanding 78.45
MDCO's Days Sales Outstanding is ranked higher than
82% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.97 vs. MDCO: 78.45 )
MDCO' s 10-Year Days Sales Outstanding Range
Min: 26.9   Max: 156.75
Current: 78.45

26.9
156.75

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -3.50
MDCO's Earnings Yield (Greenblatt) is ranked higher than
58% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MDCO: -3.50 )
MDCO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 15.2
Current: -3.5

0.1
15.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:MZN.Germany,
The Medicines Company was incorporated in Delaware on July 31, 1996. The Company is a global biopharmaceutical company focused on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on 3,000 acute and intensive care hospitals worldwide. The Company markets products including; Angiomax (bivalirudin), Recothrom Thrombin, topical (Recombinant), Cleviprex (clevidipine) injectable emulsion and Minocin IV (Minocycline for Injection). Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding. Cleviprex is an intravenous small molecule calcium channel blocker. Minocin IV is an Tetracycline-class antibiotic used for treatment of bacterial infections caused by Acinetobacter species. The Company has a pipeline of acute and intensive care hospital products in development, including five registration stage product candidates; cangrelor, oritavancin, IONSYSTM (fentanyl iontophoretic transdermal system), Fibrocaps and RPX-602, and three research and development product candidates, MDCO-216, CarbavanceTM and ALN-PCSsc. In addition to these products and product candidates company also sells a ready-to-use formulation of Argatroban and have a portfolio of ten generic drugs, referred to as acute care generic products, that have the non-exclusive right to market in the United States. The Company is currently selling three of its acute care generic products, midazolam, ondansetron and rocuronium; and also co-promote the oral tablet antiplatelet medicine BRILINTA (ticagrelor) in the United States as part of global collaboration agreement with AstraZeneca LP and the Boston Scientific Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, or the Promus PREMIER Stent System, in the United States under its co-promotion agreement with Boston Scientific Corporation, or BSX. It faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The Company and its customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which it may conduct its business. In addition to regulations in the United States, the Company is subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products.
» More Articles for MDCO

Headlines

Articles On GuruFocus.com
Chuck Royce Buys Stifel Financial, Tidewater, Alamos, Sells Kennametal, Gardner Denver, Gartner Apr 25 2013 
Weekly CFO Sells Highlight: BK, MDCO, EBAY, MS, PHMD Jan 27 2013 
Weekly CFO Sells Highlight: MDCO, SIG, VCI, PHMD, SNPS Jan 21 2013 
George Soros' Top Buys in the Last Quarter Dec 23 2011 
George Soros Buys Amazon.com Inc., Motorola Solutions, Sandisk, Sells Ralph Lauren, Dendreon, Lawson Nov 15 2011 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 100,000 Shares Mar 01 2011 
Medicines Company Reports Operating Results (10-Q) Nov 09 2010 
Medicines Company Reports Operating Results (10-Q) May 10 2010 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 181,500 Shares May 04 2010 
Medicines Company Reports Operating Results (10-Q) Nov 09 2009 

More From Other Websites
TrovaGene Inc (TROV) Sees Bridger Management Buy More Shares; Other Stocks Roberto Mignone Loves Mar 03 2015
The Medicines Company to Participate in Cowen 35th Annual Health Care Conference Feb 27 2015
CHMP RECOMMENDS JINARC® (TOLVAPTAN) FOR APPROVAL IN EU: THE FIRST PHARMACEUTICAL TREATMENT FOR... Feb 27 2015
Eight Undervalued Key Antibiotics Players Feb 25 2015
The Medicines Company to participate in 2015 RBC Capital Markets' Global Healthcare Conference Feb 20 2015
The Medicines Co. Earnings Down Y/Y, Angiomax Sales Grow - Analyst Blog Feb 19 2015
Medicines Co Earnings Call scheduled for 8:30 am ET today Feb 18 2015
Medicines Co. reports 4Q loss Feb 18 2015
Medicines Co. reports 4Q loss Feb 18 2015
Q4 2014 Medicines Co Earnings Release - Before Market Open Feb 18 2015
The Medicines Company Reports Fourth Quarter and Full Year 2014 Financial Results Feb 18 2015
Alnylam Reports Narrower Loss in Q4, Focuses on Pipeline - Analyst Blog Feb 13 2015
The Medicines Company to participate in Leerink Global Healthcare Conference Feb 05 2015
The Medicines Company to participate in Leerink Global Healthcare Conference Feb 05 2015
The Medicines Company Acquires Annovation Biopharma, Inc. Feb 04 2015
The Medicines Company to Announce Fourth Quarter and Full Year 2014 Financial Results on Wednesday,... Feb 04 2015
The Medicines Co. Gets CHMP Recommendation for 3 Drugs - Analyst Blog Jan 27 2015
The Medicines Company Receives CHMP Positive Opinions for Three Hospital Acute Care Products:... Jan 23 2015
The Medicines Company Receives CHMP Positive Opinions for Three Hospital Acute Care Products:... Jan 23 2015
MEDICINES CO /DE Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Jan 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK